JP2025508052A - Ｍｅａｉおよびｎ－アシルエタノールアミンを含む組成物およびその使用 - Google Patents

Ｍｅａｉおよびｎ－アシルエタノールアミンを含む組成物およびその使用 Download PDF

Info

Publication number
JP2025508052A
JP2025508052A JP2024553359A JP2024553359A JP2025508052A JP 2025508052 A JP2025508052 A JP 2025508052A JP 2024553359 A JP2024553359 A JP 2024553359A JP 2024553359 A JP2024553359 A JP 2024553359A JP 2025508052 A JP2025508052 A JP 2025508052A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
meai
certain embodiments
acylethanolamine
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508052A5 (https=
Inventor
ズロフ－シャニ，アディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clearmind Medicine Inc
Original Assignee
Clearmind Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clearmind Medicine Inc filed Critical Clearmind Medicine Inc
Publication of JP2025508052A publication Critical patent/JP2025508052A/ja
Publication of JP2025508052A5 publication Critical patent/JP2025508052A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024553359A 2022-03-07 2023-03-06 Ｍｅａｉおよびｎ－アシルエタノールアミンを含む組成物およびその使用 Pending JP2025508052A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317257P 2022-03-07 2022-03-07
US63/317,257 2022-03-07
PCT/IB2023/052091 WO2023170552A1 (en) 2022-03-07 2023-03-06 Compositions comprising meai and n-acylethanolamines and uses thereof

Publications (2)

Publication Number Publication Date
JP2025508052A true JP2025508052A (ja) 2025-03-21
JP2025508052A5 JP2025508052A5 (https=) 2026-03-13

Family

ID=85706794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553359A Pending JP2025508052A (ja) 2022-03-07 2023-03-06 Ｍｅａｉおよびｎ－アシルエタノールアミンを含む組成物およびその使用

Country Status (9)

Country Link
US (1) US20250302773A1 (https=)
EP (1) EP4489741A1 (https=)
JP (1) JP2025508052A (https=)
CN (1) CN119212690A (https=)
AU (1) AU2023231494A1 (https=)
CA (1) CA3244360A1 (https=)
IL (1) IL315486A (https=)
MX (1) MX2024010596A (https=)
WO (1) WO2023170552A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120225185A (zh) * 2022-09-21 2025-06-27 克力迈医药公司 5-甲氧基-2-氨基茚满(“meai”)在用于治疗代谢综合征的方法中的用途
WO2025196662A1 (en) * 2024-03-20 2025-09-25 Clearmind Labs Corp. Compositions and methods for treating eating disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
JP3342491B2 (ja) 1993-08-06 2002-11-11 ファルマシア・アンド・アップジョン・カンパニー 選択的ドーパミンｄ３リガンドとしての２−アミノインダン類
WO2005002524A2 (en) * 2003-07-02 2005-01-13 The Regents Of The University Of California COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES OF OLEOYLETHANOLAMIDE-LIKE COMPOUNDS AND MODULATORS OF PPARα
CN107406369B (zh) * 2014-12-09 2021-01-15 以西结·戈兰 放纵行为调节剂
ES2580508B1 (es) * 2016-04-11 2018-09-12 Servicio Andaluz De Salud Composiciones para la prevención y/o tratamiento de los trastornos por uso de alcohol.

Also Published As

Publication number Publication date
CN119212690A (zh) 2024-12-27
EP4489741A1 (en) 2025-01-15
AU2023231494A1 (en) 2024-09-05
MX2024010596A (es) 2025-01-09
CA3244360A1 (en) 2023-09-14
US20250302773A1 (en) 2025-10-02
WO2023170552A1 (en) 2023-09-14
IL315486A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
US20240335418A1 (en) Safer psychoactive compositions
US9763903B2 (en) Compositions and methods for treating intestinal hyperpermeability
MX2012005257A (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
CN107835695B (zh) 用于治疗自闭症的组合物和方法
MX2012014686A (es) Metodos para tratar el transtorno bipolar.
JP2025508052A (ja) Ｍｅａｉおよびｎ－アシルエタノールアミンを含む組成物およびその使用
WO2022115798A2 (en) Compositions and methods for treating migraine
CN101272776B (zh) 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途
EP1401424B1 (en) Carbamate compounds for use in preventing or treating psychotic disorders
RU2464023C2 (ru) Лекарственное средство для лечения фибромиалгии
US20160128954A1 (en) Methods of Treating Huntington's Disease Using Cysteamine Compositions
JP2025529597A (ja) メタボリック症候群の処置方法における５－メトキシ－２－アミノインダン（「ｍｅａｉ」）の使用
CN107735094A (zh) 胱氨酸‑谷氨酸转运蛋白的抑制剂的新用途
CN112822997A (zh) 用于治疗孤独症的组合物和方法
US20250325500A1 (en) Use of 5-methoxy-2-aminoindan ("meai") in methods for treating cocaine addiction
WO2022007578A1 (zh) 治疗阿尔茨海默病的组合及其应用
EP3478279A1 (en) Combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, compositions and uses thereof in the treatment of disorders associated with protein misfolding and protein aggregations
WO2024171073A1 (en) Compositions comprising 3,4-methylenedioxymethamphetamine, optionally in combination with n-acylethanolamines, and uses thereof
WO2023215338A1 (en) Compositions and methods for treating cluster headache
HK40116464A (en) Compositions and methods for treating intestinal hyperpermeability
WO2024171075A1 (en) Compositions comprising ibogaine, optionally in combination with n-acylethanolamines, and uses thereof
WO2018008733A1 (ja) 医薬組成物
HK1155659B (en) Pharmaceutical composition for treatment of fibromyalgia

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260305